Abstract:Malaria is a disease that can be cured with antimalarial drugs if treated early and appropriately. However, parasites resistant to a new drug generally emerge within a few years after large-scale applications. Artemisinin (ART or Qinghaosu) combination therapies (ACTs) have become the major treatments for malaria after the emergence of parasites resistant to almost all classes of antimalarial drugs. Parasites with delayed parasite clearance (DPC) after ART or ACT therapies have also been reported in Southeast Asia, raising concerns of total failure of ART and its derivatives. Many classes of antimalarial drugs have been introduced to successfully treat malaria infections, including chloroquine, piperaquine, primaquine, mefloquine (MQ), pyrimethamine, sulfadoxine, ART and derivatives, etc. Regrettably, many of these drugs have been abandoned by many countries in malaria endemic regions due to the emergence of drug resistant parasites. According to World Health Organization, parasite responses to a drug can be classified into four categories (S, RI, RII, and RIII): Sensitivity (S) to a drug is defined as clearance of asexual parasitemia within seven days of the first day of treatment without recrudescence; Resistance RI is defined as clearance of asexual parasitemia as in sensitive parasites, followed by recrudescence; RII resistance is indicated by marked reduction of asexual parasitemia, but no clearance; and RIII resistance shows no marked reduction of asexual parasitemia. Currently, RII and RIII resistance to chloroquine, pyrimethamine, and other drugs have been widely reported; but residence to ART remains largely at R1 level. ART resistance was initially defined as parasites with half parasite clearance time (PC1/2)>5 h under a standard ART treatment regimen (three-day artesunate treatment at 2–4 mg kg - 1 d - 1). A second measurement is in vitro ring survival assay (RSA) that was developed based on the observation that the ring stages of some parasite strains could survive a short period of ART treatment. Another indicator of increasing ART tolerance is the elevated rate of recrudescence after ART or ACT treatments. The generation of highly reactive radicals via endoperoxide cleavage is critical for ART activation. Both free ferrous iron and heme have been proposed to be the predominant iron sources for ART activation. The heme required for ART activation can be derived from the parasite’s heme biosynthesis pathway at the early ring stage and/or from hemoglobin digestion at later stages. A large number of parasite molecules have been found to bind or interact with ART, most notably the Plasmodium falciparum ATPase 6 (PfATP6 or SERCA), phosphatidylinositol-3-kinase (PfPI3K), chloroquine resistance transporter (PfCRT), and multiple drug resistance 1 (PfMDR1). Recently, a gene encoding a parasite Kelch protein (“K13”) with a six-blade propeller domain was identified as a potential molecular marker of ART resistance in vivo (DPC>5 h) and in vitro (RSA). Various antimalarial drugs such as meflouine and piperaquine have been used as partner drugs in ACTs. However, parasites resistant to these partner drugs have also been reported, which may explain the reported slow parasite clearance after ACT treatment. The success of ACTs in treating malaria infections has generated optimism and proposals for malaria eradication by mass drug administration (MDA), and successes have been achieved from several studies. However, the impact of MDA on malaria transmission in the long term, especially in low- and moderate-transmission settings, and the potential consequences of developing drug resistance, requires careful evaluation. There are a large number of studies and publications on these related subjects, and it is impossible to include or cite all the publications in this review. Additionally, some of the issues discussed here are still being debated, requiring further investigation.

‘Artemisinin Resistance’: Something New or Old? Something of a Misnomer?

Unpacking ‘artemisinin Resistance’

The artemisinin-induced dormant stages of Plasmodium falciparum exhibit hallmarks of cellular quiescence/senescence and drug resilience

Artemisinin and Malaria: Current Understandings of Drug Activation, Action, and Resistance

Artemisinin resistance and malaria elimination: Where are we now?

Increased Tolerance to Artemisinin in Plasmodium Falciparum is Mediated by a Quiescence Mechanism.

Discovery, mechanisms of action and combination therapy of artemisinin.

Antimalarial Mechanisms and Resistance Status of Artemisinin and Its Derivatives

In vitro growth competition experiments that suggest consequences of the substandard artemisinin epidemic that may be accelerating drug resistance in P. falciparum malaria

Artemisinin herbal combo breakers: navigating malaria treatment's double-edged sword

Artemisinin resistance phenotypes and K13 inheritance in a Plasmodium falciparum cross and Aotus model.

The emergence of artemisinin partial resistance in Africa: how do we respond?

Enhanced cell stress response and protein degradation capacity underlie artemisinin resistance in Plasmodium falciparum

Emergence, transmission dynamics and mechanisms of artemisinin partial resistance in malaria parasites in Africa

Plasmodium Falciparum Resistance to ACTs: Emergence, Mechanisms, and Outlook

[Research Progress on Artemisinin Resistance in Plasmodium Falciparum].

Design of novel artemisinin-like derivatives with cytotoxic and anti-angiogenic properties

Identifying a next-generation antimalarial trioxolane in a landscape of artemisinin partial resistance

Plasmodium falciparum artemisinin resistance: something gained in translation

Expanding the Therapeutic Spectrum of Artemisinin: Activity Against Infectious Diseases Beyond Malaria and Novel Pharmaceutical Developments

Artemisinin resistance in the malaria parasite, Plasmodium falciparum, originates from its initial transcriptional response